[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  19.00 3.57% 551.00 547.00 551.00 556.00 537.00 537.00 98,643 09:30:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,763

Hutchmed (china) Share Discussion Threads

Showing 3501 to 3524 of 3550 messages
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
28/10/2021
16:21
Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the issuance of US$100 million of shares at a price equivalent to US$30.5 per American Depositary Share ("ADS") via a private placement to funds affiliated with Baring Private Equity Asia ("BPEA").That was back in April 2021 and now the US price has falken below the $30.50 level.Might wake up Baring Asia if no one else.
steeplejack
28/10/2021
13:28
I have had shares in Hutch Med and have been in and out of it. As a share it's share price movement is really odd. It's almost harder to read than their results. What happens though is someone will turn the big tap on again soon and up it goes, only to cycle back down. To date I cannot see an obvious correlation to anything other than HK listing and Biden getting feisty. The company looks like a long term winner if politics stay out of it. In short term though that is not case. Currently sitting and watching again GLA
chester9
28/10/2021
13:14
SHOCKING!!!
fionascott1234
28/10/2021
08:23
Yes,looks like $30 might be tested again.Its hard to see whats going to kick this share out of its inherent lethargy.Just as well that i hold the likes of Nvidia and Thermo Scientific to compensate. If you look at the major holders in this company,they account for around three quarters of the equity.Its a fair assumption that that these holders are not flipping in and out,implying that the shares are being influenced by thin trading of the remaining 25% of the equity held by private clients and proprietary books.The shares have been falling on low volumes over the last couple of months and the collapse in the shares is clearly disproportionate,they’ve fallen by a quarter.Ordinarily,you’d see this as a buying opportunity but frankly,the share price movements of this stock seem to defy explanation.This has been going on for years.
steeplejack
27/10/2021
18:09
Yikes 450p, hoped we were at least going sideways now.
its the oxman
20/10/2021
11:18
we have the stock conmnect, over-subscribed IPO, pending DA approval of Surufatinib etc etc etc and a stock price that has just lost all of its gains of the past 6 months..........meanwhile Beigene is off to the races. Hopefully Hutchmed's time will come....
nerdofsteel
20/10/2021
08:55
As the prison governor said in the film 'Cool Hand Luke'-"What we have here is a failure to communicate".Price down again in Hong Kong in a firm market and despite chartists signalling a buy.
steeplejack
19/10/2021
15:59
Let's hope we know what we're doing.
its the oxman
19/10/2021
15:19
Also added. Fully loaded , but just couyld not resist it !!
dbadvn
15/10/2021
17:01
yes, 2025:- circa $1.4bn (circa 6x 2022) valuation = circa $25bn around £20 per share, maybe more Cashflow positive
nerdofsteel
15/10/2021
11:21
NoS, I agree. No takeover premium, no blockbuster, Chinese discrimination= follow the numbers. Probably a lot more pharmas should be rated this way in any case. Fortunately the numbers are almost certainly going to be excellent.
dbadvn
15/10/2021
08:04
Technically oversold says Zacks and expects rebound.
steeplejack
14/10/2021
22:29
Really want to have the confidence to buy more, but...
its the oxman
13/10/2021
12:54
I fear that's right.The whole Sino/US debacle has perhaps shortened time horizons and investors want to be within touching distance of profits and positive cash flow before rerating.Thus the stock becomes something of a plaything.$30 looks pretty solid as a support level of the last resort!This is the type of stock that does relatively well during a bear market.Not that i think that a crash is imminent but its more than likely that moneys going to come off the equity table given rising inflation,rising rates,profits under pressure from bottlenecks etc.We're lucky to have Captain Boris Pugwash at the helm of SS UKbusiness to tack us through the storms ;)
steeplejack
13/10/2021
07:36
looks like another of my predictions has gone pear-shaped - inclusion in the North-South Stock Connect program. Down 7% ytd despite the huge pipeline and approvals progress. Looks like the only thing the market cares about is the numbers. Maybe when the company starts generating a profit from 2025 is the time things may turn positive!
nerdofsteel
13/10/2021
00:33
steeplejack - That would probably be a good move. The share price action here is somewhat disappointing! Where has the negative news been? I have only seen positive to non-material news flow so far and yet we are down so much from the listing high in HK. Thought the HK market was going to have the opposite effect. Seems crazy!
lauders
12/10/2021
14:40
Mistakenly perhaps I like to think I have a vague sense of where stocks in my portfolio are heading and the factors that influence price movements.With Hutchmed,I have next to no idea where it's going from day to day or month to month.Next run up to hopefully 6 quid :) ,I'll be selling out.Nay worry,one thing I can rely on is the volatility will continue and who knows I might start trading the stock.
steeplejack
12/10/2021
12:59
No matter the behaviour of the FTSE, US30, Hang Seng or the Shanghai Index this has suffered a severe down-bleed than prospects would have suggested. Patience, patience they said!
fionascott1234
12/10/2021
06:38
Down to 480p in Hong Kong nearing all time low since being listed.
steeplejack
06/10/2021
21:08
Like a lot of stocks , feels more a buy than a sell now its retraced 20%. Time will tell.
its the oxman
06/10/2021
07:19
This stock simply isn't in the "zone".Concerns about China have,for now,eclipsed the benefits of the recent HK listing.However,when all said and done,the stock hasn't really gone up meaningfully for some three years.Its chopped up and down in a trading range.I'm becoming sceptical as to whether they'll be some damascene experience here which sees the stock explode to the upside on improved sentiment.Its not as if the company is lightweight at marketing,on the contrary,CH is outstanding.I lightened sometime back and will hold the remainder.China will recover in due course and i expect HMED will too but i won't be increasing my exposure to the former or the latter.HMED will have to grind out solid progress until a rerate becomes compelling.
steeplejack
05/10/2021
13:11
I think all bets are off until the Evergrande situation and the other subsequent real extate failures are resolved. Would buty more here if I could.
dbadvn
05/10/2021
11:57
Thank you.
shaker44
05/10/2021
11:09
Thank you. I hope share price will pick up after Chinese market re opens following this long national holuday
shaker44
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211129 09:49:27